Magnatuss T Syrup is a combination antitussive and antihistamine formulation containing Codeine phosphate (10 mg) and Triprolidine hydrochloride (1.25 mg) per 5 ml. Codeine, an opioid derivative, acts centrally on the medullary cough center to suppress the cough reflex, providing effective relief from dry, non-productive cough. Triprolidine, a first-generation antihistamine, exhibits anticholinergic and sedative properties, alleviating allergic symptoms such as nasal congestion, rhinorrhea, and sneezing commonly associated with upper respiratory tract infections. This synergistic combination is indicated for symptomatic management of cough and allergic manifestations in conditions like common cold, bronchitis, and other respiratory tract irritations. Magnatuss T Syrup should be administered with caution in patients with respiratory depression, asthma, or hypersensitivity to any component. It is contraindicated in children under 12 years and in patients using monoamine oxidase inhibitors. Common adverse effects may include drowsiness, dizziness, dry mouth, and gastrointestinal disturbances. Due to the presence of codeine, the syrup has potential for dependence and should be used strictly as prescribed. Dosage adjustments may be necessary in hepatic or renal impairment. Patients are advised to avoid alcohol and operating machinery during treatment. Always consult a healthcare professional before use to ensure safety and efficacy.